PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The trial will evaluate the extended bactericidal activity of 14 consecutive days of oral
administration of PA-824 at 200, 600, 1000 and 1200 mg per day in adult patients with newly
diagnosed, uncomplicated, smear positive tuberculosis. A control group will receive standard
TB treatment.